||It has been suggested that this article be merged into Mycophenolic acid. (Discuss) Proposed since September 2011.|
|Systematic (IUPAC) name|
|Licence data||EMA: , US FDA:|
|Excretion||Urine (93%), faeces (6%)|
|(what is this?)|
Mycophenolate mofetil (MMF) (brand name CellCept, compare with Myfortic - natrii mycophenolas) is an immunosuppressant and prodrug of mycophenolic acid, used extensively in transplant medicine. It is a reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH) in purine (guanine) biosynthesis which is necessary for the growth of T cells and B cells. Other cells are able to recover purines via a separate salvage pathway and are thus able to escape the effect.
MMF is also used in the treatment of autoimmune diseases, such as Behçet's disease, pemphigus vulgaris, systemic lupus erythematosus and refractory incomplete lupus erythematosus. Suppressing T cells and B cells stops them from attacking healthy cells, but also weakens their ability to defend against infections.
The chemical name for mycophenolate mofetil is 2-morpholinoethyl (E)-6-(1,3-dihydro-4-hydroxy-6-methoxy-7-methyl-3-oxo-5-isobenzofuranyl)-4-methyl-4-hexenoate. Its empirical formula is C23H31NO7 and molecular weight 433.50. Mycophenolate mofetil is morpholinoethyl ester of mycophenolic acid, which is used to mask the carboxyl group. Mycophenolate mofetil is reported to have pKa values 5.6 for the morpholino moiety and 8.5 for the phenolic group.
Side-effects and adverse reactions
Among the most common side-effects of this drug is increased blood cholesterol levels. Other changes in blood chemistry such as hypomagnesemia, hypocalcemia, hyperkalemia, and an increase in BUN are regularly noted. Coughing and issues with breathing are not uncommon - pleural effusions being noted in approximately 1:3. There is a similar occurrence ratio of Infections; with leukopenia and anemia reflecting the immunosuppressive and myelosuppressive nature of the drug. Back and abdominal pain – in addition to headache, nausea, diarrhea, and fever – are also experienced with this drug.
More rarely, various neoplasia occur: melanoma, lymphoma, other malignancies having an occurrences of 1 in 20 to 1 in 200, depending on the type, with Neoplasia in the skin being the most common site.
Given that this is a pro-drug of mycophenolic acid, the adverse reactions and side-effects noted in that article are also relevant.
- "CellCept®" (PDF). TGA eBusiness Services. Roche Products Pty Limited. 13 December 2012. Retrieved 25 February 2014.
- Fulton B, Markham A. "Mycophenolate mofetil : a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation." Drugs. 1996, 51(2):278-98.
- Boehm I et al. Chilblain lupus erythematosus Hutchinson: successful treatment with mycophenolate mofetil. Arch Dermatol 2001;137:235 – 236 http://archderm.jamanetwork.com/article.aspx?articleid=478189